Sun Pharmaceutical to discontinue certain non-strategic businesses of Ranbaxy

21 Jul 2015 Evaluate

Sun Pharmaceutical Industries has decided to discontinue certain non-strategic businesses of Ranbaxy Laboratories. This move is a part of the integration process. The company expects to incur certain integration charges in order to generate long-term synergies from this merger. The company has embarked on various consolidation initiatives globally to drive future growth and profitability and to enhance long-term shareholder value.

The company also continues to allocate significant resources to R&D in order to strengthen the specialty pipeline including patented products and complex generics. This will mandate increased R&D investments including that for the development of MK-3222.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.


Sun Pharma Inds. Share Price

1639.30 7.65 (0.47%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×